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In 2017 the cervical cancer screening program in The Netherlands will be revised. Cervical smears will primarily
be tested for the presence of high-risk human papillomavirus (hrHPV) instead of cytology, and vaginal self-sam-
pling will be offered to non-responders. This includes a potential risk that part of the women who would other-
wise opt for a cervical smear will wait for self-sampling. However, self-sampling for hrHPV in a responder
population has never been studied yet. The aim of this study was to investigate the applicability and accuracy
of self-sampling in detecting hrHPV in a screening responder population. A total of 2049 women, aged 30–
60 years, participating in the screening program in The Netherlands were included from April 2013 to May
2015. After they had their cervical smear taken, women self-collected a cervicovaginal sample with a brush-
based device, the Evalyn Brush. Both the cervical smear and self-sample specimen were tested with the COBAS
4800 HPV platform. The hrHPV prevalence was 8.0% (95% CI 6.9–9.2) among the physician-taken samples, and
10.0% (95%CI 8.7–11.3) among the self-samples. Therewas 96.8% (95%CI 96.0–97.5) concordance of hrHPVprev-
alence between self-samples and physician-taken samples. Women in our study evaluated self-sampling as con-
venient (97.1%), user-friendly (98.5%), and 62.8% preferred self-sampling over a physician-taken sampling for the
next screening round. In conclusion, self-sampling showed high concordance with physician-taken sampling for
hrHPV detection in a responder screening population and highly acceptable to women. Implementation of HPV-
self-sampling for the responder population as a primary screening tool may be considered.
©2018TheAuthors. Publishedby Elsevier Inc. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cervical cancer is the fourthmost common cancer in womenworld-
wide, with an estimated 530,000 new cases in 2012 (Globocan, n.d.),
and approximately 270,000 deaths annually. Nationwide, cytology
based cervical cancer screening programs have proven to be effective
in reducing both the incidence and mortality of cervical cancer (Arbyn
et al., 2009). Cervical cancer screening was introduced in The
Netherlands in 1988, and revised in 1996 in a nationwide cytology
based 5-yearly screening program for women aged 30–60 years. De-
spite the signiﬁcant decrease in incidence of cervical carcinoma. Howev-
er, cytology based screening has resulted in many false negative results
with a sensitivity of only 30–87% (Nanda et al., 2000).
HPVDNA testing can be performed on physician-takenmaterial, and
depending on the particular HPV test and workﬂow used, on self-sam-
pled material (Eperon et al., 2013; Stanczuk et al., 2015; Arbyn et al.,
2014). Moreover, primary high-risk human papillomavirus (hrHPV)
testing has been shown to be more sensitive than cytology, and per-
forms better in a population entering the screening program (Ronco et
al., 2010; Ronco et al., 2014; Rijkaart et al., 2012; Naucler et al., 2007;
Kitchener et al., 2009). Based on extensive and accumulating scientiﬁc
evidence, theMinistry of Health, Welfare and Sports in the Netherlands
has decided to revise the screening program in 2017. Cervical smears
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will primarily be tested for the presence of hrHPV DNA instead of cytol-
ogy, with reﬂex cytology in case of a positive hrHPV test (Standpunt
minister van VWS screening op baarmoederhalskanker, 2013).
Previous studies have shown that vaginal self-sampling is a well-ac-
cepted alternative for a physician-taken cervical smear for non-re-
sponders in organized primary hrHPV based screening, and it
increases the screening participation rate (Bosgraaf et al., 2014; Gok et
al., 2010; Gok et al., 2012a; Gok et al., 2012b; Bosgraaf et al., 2015;
Schmeink et al., 2011). Vaginal self-samples and physician-taken sam-
ples show similar test accuracy in detecting cervical intraepithelial neo-
plasia grade 2 or worse (CIN2+), provided that the test and the self-
sampling device have been validated both individually and in a com-
bined method (Arbyn et al., 2014; Schmeink et al., 2011; Snijders et
al., 2013; Stanczuk et al., 2016). In the revised Dutch screening program
vaginal self-sampling will be available for non-responders (Ministry of
Health WaS, n.d).
In the responder screening population the preferred method of
screening is still unknown, and it remains to be determined whether
self-sampling is comparable to physician sampling in detecting cervical
abnormalities. Therefore, the VERA (Validation of the Evalyn brushwith
the Roche cobas 4800 hrHPV Test) study has been designed. The objec-
tives of the VERA study were to investigate concordance in hrHPV pos-
itivity and HPV 16/18 genotypes between self-collected samples, using
the Evalyn brush, and physician-taken samples, and the acceptability
of self-sampling among a responder population of the Dutch cervical
screening program.
2. Materials and methods
2.1. Study population
The Dutch screening program is a nationwide program targeting
women aged 30–60 years. Women are invited at 5-year intervals for a
cervical smear, generally taken by their physician. In the current
study, 2460 women, aged 30–60 years and living in the regions of Nij-
megen and ‘s-Hertogenbosch in the Netherlands, participated in the
VERA study.
2.2. Clinical specimen collection
The participants had their regular cervical smear taken by their phy-
sician as part of the nationwide program. A trained physician obtained a
liquid-based cytology sample using a Rovers Cervex-Brush (Rovers
Medical Devices B.V., Oss, Netherlands). The Cervex-Brush was rinsed
in ThinPrep medium (Hologic, Marlborough, MA) in the Nijmegen re-
gion and in SurePath medium (Klinipath BV, Duiven, Netherlands) in
the ‘s-Hertogenbosch region. Cytological examination and classiﬁcation
were performed at the local laboratory according to the CISOE-A (com-
position, inﬂammation, squamous epithelium, other and endometrium,
endocervical columnar epithelium, and adequacy of the smear) classiﬁ-
cation, which can easily be translated into the Bethesda 2001 classiﬁca-
tion (Bulk et al., 2004). The VERA study was not allowed to interfere in
the cervical cancer screening program, according to the Dutch law.
Therefore, the self sample was always taken after the physician taken
sample, and referral was based on the outcome of the cytology assess-
ment, and not of the obtained hrHPV result from the study.
2.3. Self-sampling procedures
After informed consent, and at the time of the appointment with
their physician for their scheduled cervical smear, the participants also
received a self-sampling kit including a self-sampling device (Evalyn
Brush, Rovers Medical Devices B.V., Oss, Netherlands). The Evalyn
Brush is about 20-cm long and consists of a transparent case with
wings that control the depth of insertion into the vagina. After the de-
vice has been inserted up to its wings, pushing the plunger toward the
casingwill push the brush out into the vagina. The brush needs to be ro-
tated ﬁve times; each rotation generates an audible click. After rotation,
the brush can be removed from the vagina, and pulled back into the
case. A cap is to be clicked onto the case and the brush can be directly
sent to the laboratory. The self-sampling kit also includes an explanato-
ry letter, an informed consent form, user instructions (written and
drawn), a short questionnaire, and a return envelope with the address
of the laboratory. Women self-collected a cervicovaginal sample with
the Evalyn Brush either at home or in the physician's practice, in either
case after the physician collected sample was taken. The women were
asked to return the dry brushwith the self-sampledmaterial, the signed
informed consent form, and the questionnaire by regular mail.
2.4. Specimens preparation
Upon arrival of the dry brush devices at the laboratory, the brush tips
were suspended in 4.5ml of Preservcytmedium (Hologic,Marlborough,
MA). The vials were vortexed for 3 × 15 s, stored overnight at 4 °C, and
again vortexed for 2 × 15 s, before the brushes were removed and
discarded.
A total of 3 ml was collected from the physician obtained samples,
and stored and transported at room temperature to the department of
Medical Microbiology, Radboudumc, Nijmegen, Netherlands, for molec-
ular hrHPV DNA testing.
2.5. Cobas 4800 HPV test
The physician-collected residual liquid-based cytology (LBC) speci-
mens and the self-sampled specimens were vortexed before being
placed in the cobas 4800 for hrHPV testing using the clinically validated
Roche cobas 4800 HPV Test to detect 12 hrHPV types (hrHPV31, -33,
-35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) as a pooled result,
and simultaneously provide speciﬁc genotyping information for HPV-
16 and HPV-18. The cobas 4800 HPV Test features automated sample
preparation combined with real-time PCR technology. β-globin from
cellular input is used as an internal control to assess specimen adequacy
and identify specimens containing factors that inhibit the ampliﬁcation
process.
2.6. Questionnaires
To investigate the acceptability of the Evalyn Brush, all womenwere
asked to ﬁll out a short questionnaire to record their experience, their
response to the instructions, and their assessment of the convenience
of the Evalyn Brush. Participants were also asked whether they pre-
ferred self-sampling or physician sampling for the next screening
round. All questionnaires were collected and analyzed centrally. Cardiff
Teleform Software (version 10.1, 2010; Cambridge, UK)was used to de-
sign the questionnaire and record the data.
2.7. Outcome measures
The primary outcome measure of the VERA-study was concordance
in hrHPV positivity between self-collected samples, using the Evalyn
brush, and physician-taken samples. Furthermore, we investigated
hrHPV genotypes 16 and 18, and the acceptability of self-sampling in a
Dutch cervical screening responder population. For comparison of the
presence of HPV-16, HPV-18 and 12 other hrHPV genotypes between
the two samples, we used the following terminology; identical, concor-
dant or discordant. An identical result is determined if results from all
three cobas HPV channels (16, 18, and 12 other hrHPV genotypes)
were equal; concordance is determined as at least one identical geno-
type in both samples; and discordance is determined as no similarities
in the genotypes.
Follow-up outcomes of all participants were retrieved from the na-
tionwide network and registry of histology and cytology database
97P.J.W. Ketelaars et al. / Preventive Medicine 101 (2017) 96–101
(PALGA). The latest diagnosis was registered.When histological and cy-
tological diagnoses were both available in the follow-up period until
June 2015, only histological results were included in analysis. All cyto-
logical and histological ﬁndings recorded before June 2015were includ-
ed in our analysis.
2.8. Statistical analysis
Weaimed to include 135hrHPV positive cases in order to reliably as-
sess concordance between physician-taken samples and self-samples.
The overall study aim was to target a responder population of 3000
women, with an estimated hrHPV positivity of 4.5%. Analysis of the
ﬁrst 1500 samples revealed an hrHPV positivity rate of 8%, leading to
an adjustment of the sample size calculation. With 8% hrHPV positivity
only 2000 sampleswere needed in order to detect concordancewith the
same reliability. In the analysis of the questionnaires the percentages
were calculated for the women who answered the question. Concor-
dance was calculated, and a McNemar test for correlated proportions
comparing the hrHPV positive portion of self-sampling with the
hrHPV positive portion of physician sampling, was performed on the
total group as well as per age group.
3. Results
3.1. Patient characteristics
Samples were collected between April 2013 and September 2014. In
total 2460 women participated. From 316 women no cervical smear
and/or self-sample was received. Twenty-eight women were excluded
because 14 physician-taken specimens, and 14 self-sampling specimens
tested β-globin negative. Another 20 cervical smears and 47 self-sam-
pling specimenswere excluded because of an invalid test result because
of too much blood or mucus. Therefore, in total 2049 women with both
a self-sample and physician-taken test result were enrolled.
3.2. HPV prevalence
HrHPV prevalence was 8.0% (163/2049; 95% conﬁdence interval
[95% CI], 6.9 to 9.2) among the physician-taken samples, and 10.0%
(204/2049; 95% CI, 8.7 to 11.3) among the self-samples (Table 1). The
hrHPV prevalence in both the physician-taken samples and the self-
samples decreased with age from respectively 18.4%, and 20.0% in
women aged 29–33 to 4.7%, and 5.9% in women aged 59–63. (Table 2).
Overall concordance between self-samples and physician-taken
samples was 96.8% (Table 1). Using the physician samples result as ref-
erence, the proportion of true positive self-samples was 92.6% (151/
163; 95% CI, 87.6 to 95.8), while the proportion of true negative self-
samples was 97.2% (1833/1886; 95% CI, 96.3 to 97.8). The McNemar
test for correlated proportions was highly signiﬁcant (p b 0.000002) in-
dicating that the proportions are not comparable, although this differed
between the age groups (Table 2).
3.3. HPV genotyping
The HPV genotypes detected by the cobas 4800 HPV Test in the phy-
sician-taken smear were hierarchically based on oncogenicity for cervi-
cal cancer. A total of 43 out of 2049 samples (2.1%) showed single or
multiple infections with genotype HPV-16; 12 samples (0.6%) showed
single or multiple infections with HPV-18 excluding any coinfections
with HPV-16. The remaining 108 samples (5.3%) showed single or mul-
tiple infections with non-16/18-HPV genotypes.
In 51 self-samples (2.5%), single or multiple infections with geno-
type HPV-16 were found, and 11 (0.5%) single or multiple infections
with HPV-18 (excluding coinfections with HPV-16). In the non-16/18
HPV genotypes 142 (6.9%) samples were detected.
An identical result was found in 96.4% (1976/2049) of the samples.
Analysis showed a concordance of 96.8% (1984/2049), and a discor-
dance of 3.2% (65/2049). Forty-two out of 65 discordant samples tested
non-16/18 HPV genotype positive in self-sampling, and hrHPV negative
in the physician sample. Table 3 shows the results for HPV detection
separating HPV 16/18 from the other hrHPV types. The concordance
for HPV16 and/or 18 positives is 99.1% (62 (3.0%) HPV 16/18 positives
in self-sampling, and 55 (2.7%) in physician sampling), while for
hrHPV positives non-HPV16/18 the concordance is 97.0% (164 (8.0%)
HPV 16/18 positives in self-sampling, and 128 (6.3%) in physician sam-
pling). TheMcNemar test for correlated proportions was not signiﬁcant
for HPV16 and/or 18 positives, but highly signiﬁcant for non-HPV16/18
positive samples, indicating that regarding HPV 16/18 detection, the
proportions are equal, and that the differences in proportions are main-
ly caused by non-HPV 16/18 types.
3.4. Detection rate of CIN2 or worse (CIN2+)
Follow-up outcomes were retrieved from the nationwide network
and registry of histology and cytology database (PALGA). All 21
women with HSIL/CIN2+, had hrHPV identiﬁed on their physician-ob-
tained sample, whereas 19 (90.5%) also had hrHPV detected on their
self-sampled material (Table 4). Two CIN3 results in group D were
missed by hrHPV testing on self-sampled material (both women be-
tween 30 and 35 years). Both women did not report any problems
with performing the self-sample.
3.5. Questionnaires
A total of 2194 out of 2460 questionnaires (89.2%) were returned.
The mean age of the women who returned a questionnaire was
43.4 years (range, 29–61 years).
Women had the opportunity to do the self-sample at the physician's
practice (7.1%; 153/2166) or at home (92.9%; 2013/2166). The user
friendliness of the self-sampling device was rated good to excellent by
98.5% of the women.
N95.8% of thewomenexperienced noproblems during the use of the
self-sampling device. A total of 17 women (0.8%) reported uncertainty
about performing the test correctly. In 99.2% of the cases women were
conﬁdent in performing the self-sampling correctly.
Table 1
Concordance for hrHPV between self-sampling and physician sampling.
Self-sampling Total (%)
hrHPV positive (%) hrHPV negative (%)
Physician sampling hrHPV positive (%) 151 (7.4) 12 (0.6) 163 (8.0)
hrHPV negative (%) 53 (2.6) 1833 (89.5) 1886 (92.0)
Total (%) 204 (10.0) 1845 (90.0) 2049 (100.0)
Note: This study was conducted in the Netherlands from April 2013 to May 2015.
McNemar test for correlated proportions comparing hr-HPV positive portion of self sampling with positive portion of physician sampling, p b 0.000001.
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Overall, most women (62.7%) preferred the self-sampling over a
physician-taken smear, 24.8% preferred a physician-taken smear for
the next screening round and 11.9% had no preference for either self-
sampling or physician sampling. There were no notable differences be-
tween the age groups (Table 5).
The convenience of self-sampling in comparison with a physician-
taken sample was rated good to excellent by 97.1% of the women
(2100/2163).
4. Discussion
This study shows a high concordance in hrHPV prevalence between
self-samplingmaterial and physician samplingmaterial, especially with
regard to HPV 16 and/or 18 positivity. Furthermore, the brush-based
Evalyn device provided a well-accepted self-sampling method for
women participating in the cervical screening program. We showed
that self-sampling for hrHPV DNA in a Dutch responder screening pop-
ulation is well accepted, and is rated as highly user-friendly. Over 95% of
enrolled women found self-sampling convenient and user-friendly.
Most women (62.8%) preferred self-sampling over a physician-taken
smear for the next screening round. To the best of our knowledge, no
other studies investigated hrHPV concordance between a validated
brush-based self-sampling device and physician-taken sample in a re-
sponder screening populationwith a clinically validated and automated
PCR platform (Meijer et al., 2009).
Current and prior studies have shown that self-sampling for hrHPV
DNA is a well-accepted screeningmethod for women non-participating
in the regular cervical screening program. Bosgraaf et al. showed in a
previous large self-sampling study among non-responders that 80.5%
preferred self-sampling with a brush-based device over a physician-
taken smear (Bosgraaf et al., 2015). Szarewski et al. demonstrated in
an English screening population that 73% preferred to use the self-sam-
pling at home rather than come to the clinic (Szarewski et al., 2007). The
only limitation of self-sampling is the uncertainty about performing the
self-sampling correctly.
In previous studies, HPV self-samplingwas offered to non-responder
women, i.e. women who were never or irregularly screened. In these
studies the hrHPV prevalence was 8.3 to 10.3% (Gok et al., 2010; Gok
et al., 2012b; Bosgraaf et al., 2015). The hrHPV prevalence of 8.0% in
the physician-taken smears in the current study is similar to the preva-
lence in the non-responder studies in the Netherlands (Gok et al., 2010;
Gok et al., 2012b; Bosgraaf et al., 2015; Verhoef et al., 2014a). This is sur-
prising as former studies found generally a prevalence of 5% in a re-
sponder population (Rijkaart et al., 2012). This can be due to the
technique used (GP5+/6 + -PCR versus cobas hrHPV Test), to demo-
graphic factors or to a possible selection bias in the population analyzed.
The difference in higher prevalence of hrHPV in self-samples (10%)
compared with physician-taken samples (8%) is in line with previous
studies showing higher HPV prevalence in self-sampling compared to
physician collected sample (Salmeron et al., 2003; Holanda et al.,
2006; Girianelli et al., 2006). Indeed, the signiﬁcant result of the
McNemar test for correlated proportions indicate a true difference in
HPV positivity. Additional analysis showed that this difference in pro-
portion is mainly caused by detection of non-HPV 16/18 types in self
samples.With self-sampling both the cervical and vaginal area are sam-
pled. This may result in a higher non-HPV 16/18 detection rate and thus
self-sampling may not always be a true reﬂection of the cervical hrHPV
ﬂora.
Table 2
Participation rate and prevalence of hrHPV, categorized by age.
Physician sampling Self-sampling
hrHPV hrHPV hrHPV hrHPV
Age category (in years) Participants per age group Positive (%) Negative (%) Positive (%) Negative (%) P-value⁎
29–33 245 45 (18.4) 200 (81.6) 49 (20.0) 196 (80.0) 0.34
34–38 240 20 (8.3) 219 (91.3) 28 (11.7) 212 (88.3) 0.02
39–43 316 22 (7.0) 288 (91.1) 30 (9.5) 286 (90.5) 0.07
44–48 401 31 (7.7) 370 (92.3) 40 (10.0) 361 (90.0) 0.01
49–53 416 24 (5.8) 392 (94.2) 30 (7.2) 386 (92.8) 0.07
54–58 327 16 (4.9) 311 (95.1) 22 (6.7) 305 (93.3) 0.18
59–63 85 4 (4.7) 81 (95.3) 5 (5.9) 80 (94.1) 1.00
Unknown 19 – 19 (100.0) – 19 (100.0) 1.00
Total 2049 163 (8.0) 1886 (92.0) 204 (10.0) 1845 (90.0) b0.000001
Note: This study was conducted in the Netherlands from April 2013 to May 2015.
⁎ McNemar test for correlated proportions.
Table 3
Concordance for HPV 16/18, and non-16/18 hrHPV.
Self-sampling Total (%)
HPV 16/18 positive HPV 16/18 negative
Physician sampling HPV 16/18 positive 50 5 55 (2.7)
HPV 16/18 negative 12 1982 1994 (97.3)
Total (%) 62 (3.0) 1987 (97.0) 2049 (100.0)
Non-16/18 hrHPV positive Non-16/18 hrHPV negative
Physician sampling Non-16/18 hrHPV positive 117 11 128 (6.3)
Non-16/18 hrHPV negative 47 1874 1921 (93.7)
Total (%) 164 (8.0) 1885 (92.0) 2049 (100.0)
Concordance for HPV 16/18 positive is 2032/2049 = 99.1%.
Concordance for non-16/18 hrHPV positive is 1991/2049 = 97.0%.
McNemar test for correlated proportions HPV 16/18 positive samples p= 0.14.
McNemar test for correlated proportions non-16/18 hrHPV positive samples p b 0.000002.
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High hrHPV prevalence rates may lead to a high referral rates. For
this reason a triage test is often suggested to reduce referral rates and
prevent overtreatment. It has been shown that cytology triage is not
possible on self-sampled material (Arbyn et al., 2012). HrHPV genotyp-
ing during cervical cancer screening might improve cervical cancer
screening to become more effective, because it might identify women
with a higher risk of cervical cancer (Kjaer et al., 2010). HPV-16 and
HPV-18 are the most oncogenic hrHPV genotypes (Kjaer et al., 2010).
Using immediate genotyping with the COBAS platform to make a dis-
tinction between a non-16/18 HPV (hrHPV31, -33, -35, -39, -45, -51,
-52, -56, -58, -59, -66, and -68, a pooled result), and a HPV-16 and/or
HPV-18 test result, may positively inﬂuence the referral rate. This
study shows that especially HPV-16 and 18 are equally well detected
with self-sampling compared to physician sampling, as the McNemar
test indicated identical proprotions.
The discordance between physician collected and self-sampled
specimens was particularly notable for non HPV-16/HPV-18 positive
samples in the self-sampling group versus negative in physician-taken
group. No earlier research has reported on the differences in non HPV-
16/HPV-18 between different genital regions. An explanation for the
discordance of hrHPV could be that with self-sampling a different ana-
tomic area is sampled. With self-sampling both the cervical and vaginal
area are sampled, compared to only the cervical area in the physician-
taken sample.
Another direct triage strategy could be DNA methylation. Recent
studies have shown that DNAmethylation analysis directly on self-sam-
pled brush-based and lavage-based specimens is feasible and showed a
high correlation with matched physician-taken samples (Boers et al.,
2014; Verhoef et al., 2014b). DNAmethylation could be an attractive al-
ternative to cytology. Since, the need for an extra physician-taken cervi-
cal smear can be eliminated. This could lead to more compliance and
less loss to follow-up. Further research is necessary to investigate
which triage strategy ismost effective in the new cervical cancer screen-
ing program.
In this study, two cases with CIN 3 were not detected with self-sam-
pling, but were hrHPV positive on a physician taken sample. This could
be explained because women always had to take the self sample after
the physician taken smear, which may have negatively inﬂuenced the
self sample results. However, CIN detection relied heavily on cytology
only, so it is unclear how many CIN 3 may have been present in the
self-sampling positive/physician taken sample negative group only in
a randomized trial, which would include patient management based
on the hrHPV result, instead of cytology may elucidate this issue. How-
ever, a recent meta-analysis in screening populations showed a lower
pooled sensitivity of HPV testing on self-samples than HPV testing on
a physician-taken sample (ratio 0.84 [0.77–0.92], for CIN2+ detec-
tion.(6)Most studies in thismeta-analysis were done usingHybrid Cap-
ture 2 (HC2) for HPV detection. It has been shown before that
hybridization performs worse on self samples than PCR assays. There-
fore more comparison studies are needed to resolve this issue.
4.1. Strengths and limitations
Strengths of this study include the fact that hrHPV testing was per-
formed both on self-sampled and physician-sampled material of the
samewomen, with a combination of a clinically validated self-sampling
device as well as a clinically validated HPV assay. This study also mea-
sured the acceptability of the self-sampling device, and assessed atti-
tudes toward self-sampling among responders in a Dutch real-world
cervical cancer screening setting.
A limitation of our study is that the self-sample was always the sec-
ond sample to be collected. This may have affected the concordance
given that the initial physician collected sample could have depleted
the amount of available hrHPV. With this sample consecution there
was an exclusion of 121 out of 2170 samples, because these samples
contained too much blood for reliable testing. In other studies the inva-
lid rate of a brush-based self-sampling device is b0.5%. Additionally, the
follow-up was not based on the hrHPV result. Therefore, the follow-up
outcomes retrieved from PALGAwere unable to show howmany physi-
cian-taken samples missed CIN2+.
5. Conclusion
Self-sampling with the Evalyn Brush compared with the cobas 4800
platform showed a high concordancewith physician-taken sampling for
hrHPV detection in women participating in the regular cervical screen-
ing program, especially regarding HPV 16/18 detection. With self-sam-
pling more non-HPV 16/18 infections are detected. Self-sampling is
highly acceptable to women, and a well-accepted alternative to physi-
cian-taken samples in a responders screening population. On the basis
of the results of this study, implementation of HPV-self-sampling in a
responder population as a primary screening tool may be considered.
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Table 4
Aggregated results per group.
CS+/SSD+ CS-/SSD- CS-/SSD+ CS+/SSD- Total
Cytology
Invalid − 3 1 − 4
NILM 112 1801 47 9 1969
ASC-US/AGC 6 9 2 − 17
LSIL 2 − − 1 3
HSIL 4 − − − 4
Histology
No CIN 7 8 9 − 17
CIN1 5 − − − 5
CIN2 4 − − − 4
CIN3 11 − − 2 13
Unknown − 12 1 − 13
Total 151 1833 53 12 2049
Note: This study was conducted in the Netherlands from April 2013 to May 2015.
CS = hrHPV testing on a physician-taken cervical smear.
SSD = hrHPV testing on a self-sampling device.
Table 5
Preference of screening method in the next screening round, categorized by age.
Age
category
(in years)
Self-sampling
(%)
Physician-taken
smear (%)
No
preference
(%)
No test next
screening
round (%)
Total
29–33 174 (65.4) 59 (22.2) 32(12.0) 1 (0.4) 266
34–38 156 (61.7) 65 (25.7) 31 (12.3) 1 (0.4) 253
39–43 211 (62.4) 79 (23.4) 47 (13.9) 1 (0.3) 338
44–48 286 (63.3) 122 (27.0) 44 (9.7) – 452
49–53 263 (61.4) 113 (26.4) 51 (11.9) 1 (0.2) 428
54–58 201 (61.5) 80 (24.5) 45 (13.8) 1 (0.3) 327
59–63 53 (67.1) 14 (17.7) 5 (6.3) 7 (8.9) 79
Total 1344 (62.7) 532 (24.8) 255 (11.9) 12 (0.6) 2143
Note: This study was conducted in The Netherlands from April 2013 to May 2015.
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